1 Effective January 1, 2014, Amgen acquired rights to pegfilgrastim and filgrastim from Roche. Roche had held those rights under license from Kirin-Amgen (a joint venture between Amgen and Kirin Holdings, of Japan), in Eastern Europe, Latin America, Asia, the Middle East, and Africa since 1989. See Amgen announcement of October 22, 2013: http:///media/media_pr_?releaseID=1866783 . Kyowa Hakko Kirin retains rights to pegfilgrastim under the name Peglasta ® in Singapore and Thailand, and under the name Neulasta ® in Taiwan. Kyowa Hakko Kirin retains rights to filgrastim under the name Gran in China, Japan, South Korea, Malaysia, and Taiwan. Kirin reports sales under the combined listing of “Gran.”
2 Pfizer lists separately the Lyrica revenues generated in all of Europe, Russia, Turkey, Israel, and Central Asia countries ($801 million in 2016, $ billion in 2015). Those revenues are listed by Pfizer’s “Essential Health” operating segment, while its “Innovative Health” segment records Lyrica revenues generated elsewhere in the world, including the . ($ billion in 2016, $ billion in 2015).